Phase 3 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)
Latest Information Update: 20 Sep 2021
At a glance
- Drugs Reltecimod (Primary)
- Indications Acute kidney injury
- Focus Registrational; Therapeutic Use
- Acronyms REAKT
- Sponsors Atox Bio
- 10 Jun 2020 Status changed from recruiting to discontinued.
- 01 May 2019 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 01 May 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.